South Africa Drops J&J Bedaquiline Scrutiny After Generic Market Opens Up

J&J Agrees To Withdraw 2027 Secondary Patent; 40% Price Cut Agreed With Buyer

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.